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Abstract
Introduction: Sex differences have already been reported in sub-Saharan Africa for attrition and immunological response after
antiretroviral therapy (ART) initiation, but follow-up was usually limited to the first two to three years after ART initiation. We
evaluated sex differences on the same outcomes in the 10 years following ART initiation in West African adults.
Methods: We used cohort data of patients included in the IeDEA West Africa collaboration, who initiated ART between 2002
and 2014. We modelled no-follow-up and 10-year attrition risks, and immunological response by sex using logistic regression
analysis, survival analysis with random effect and linear mixed models respectively.
Results: A total of 71,283 patients (65.8% women) contributed to 310,007 person-years of follow-up in 16 clinics in eight
West African countries. The cumulative attrition incidence at 10-year after ART initiation reached 75% and 68% for men and
women respectively. Being male was associated with an increased risk of no follow-up after starting ART (5.1% vs. 4.0%,
adjusted Odds Ratio: 1.25 [95% CI: 1.15 to 1.35]) and of 10-year attrition throughout the 10-year period following ART initia-
tion: adjusted Hazard Ratios were 1.22 [95% CI: 1.17 to 1.27], 1.08 [95% CI: 1.04 to 1.12] and 1.04 [95% CI: 1.01 to 1.08]
during year 1, years 2 to 4 and 5 to 10 respectively. A better immunological response was achieved by women than men:
monthly CD4 gain was 30.2 and 28.3 cells/mL in the first four months and 2.6 and 1.9 cells/lL thereafter. Ultimately, women
reached the average threshold of 500 CD4 cells/lL in their sixth year of follow-up, whereas men failed to reach it even at the
end of the 10-year follow-up period. The proportion of patients reaching the threshold was much higher in women than in
men after 10 years since ART initiation (65% vs. 44%).
Conclusions: In West Africa, attrition is unacceptably high in both sexes. Men are more vulnerable than women on both attri-
tion and immunological response to ART in the 10 years following ART initiation. Innovative tracing strategies that are sex-
adapted are needed for patients in care to monitor attrition, detect early high-risk groups so that they can stay in care with a
durably controlled infection.
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1 | INTRODUCTION
In 2016, the World Health Organization recommended that
all HIV-infected patients be treated with antiretroviral therapy
(ART) irrespective of CD4-cell counts and clinical stage [1].
The introduction of this universal treatment policy has been
an important and positive milestone in the fight against HIV/
AIDS. This, however, led to an increased number of patients
eligible for ART, thus challenging the delivery of adequate HIV
care to both newly eligible patients and those already on ART
in resource-limited settings.
ART improves survival and quality of life in HIV-positive
patients, but only when they remain permanently in care and
adhere to treatment [2]. As the number of people living with
HIV on ART increases, concerns have been raised for long-
term retention and response to treatment. Several studies
have shown that retention of patients on ART was suboptimal
across different settings [3-9]. A systematic review on the
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data from 13 sub-Saharan African countries showed 75% and
62% retention rates at 12 and 24 months respectively [9].
Similarly, a meta-analysis on HIV-positive adults in 42 low-and
middle-income countries reported retention rates of 78%,
71% and 69% at 12, 24 and 36 months respectively [4]. More
recently, the International epidemiology Databases to Evaluate
AIDS (IeDEA) group reported that only 52% of African
patients were retained in care five years following ART initia-
tion. This rate improved to 66% after accounting for undocu-
mented mortality and self-transfers [6].
Factors behind poor retention have been extensively inves-
tigated [8-16], and body of evidence has shown that the rea-
sons behind the loss of patients were generally multi-factorial.
Sex was identified, however, as one of the most consistent
determinants for loss to care, with male patients showing
excess mortality [17] and higher risk of attrition [8,14,18].
Retention in care is the first-level indicator to estimate ART
programme’s effectiveness [2,19-21] and to evaluate progress
towards the United Nations AIDS Programme (UNAIDS) 90-
90-90 and 95-95-95 targets [22,23]. However, being retained
in care does not guarantee adequate treatment response. In
sub-Saharan Africa, CD4 count is the most commonly available
biological marker allowing evaluation of treatment response to
ART. Previous studies have reported gender differences in
immunological response with better immune reconstitution for
women than for men [24-26].
Retention in care and immunological response in ART-
treated patients have been reported already in many African
settings, but less evidence is available from West Africa where
the burden of HIV is somewhat lower than in other African
regions but where the coverage of care and ART programmes
is also far less advanced [27]. In addition, the majority of the
available reports assessed the programmatic and clinical out-
comes at two to three years following ART initiation only. A
previous study on attrition in West Africa did not go further
than 12 months of follow-up on ART [3]. Little is therefore
known about how HIV care programmes retain patients in
care and provide adequate services in a longer time span and
whether the sex difference in attrition persists. We evaluated
10-year attrition and immunological response to ART by sex
among HIV-infected adults followed in large HIV care pro-
grammes throughout West Africa.
2 | METHODS
2.1 | The IeDEA West Africa collaboration
The IeDEA international research consortium was established
in 2006 by the National Institute of Allergy and Infectious
Diseases (NIAID) to consolidate, curate and analyse data on
care and treatment of HIV to evaluate the outcomes of peo-
ple living with HIV/AIDS. IeDEA collects such data from seven
international regional data centres, including four in Africa,
and one each in the Asia-Pacific region, the Central/South
America/Caribbean region and North America [28].
We conducted a cohort analysis on the data extracted from
the IeDEA West Africa collaboration [29]. The present data
set included medical records from 16 HIV-care centres over
eight countries participating in this network throughout West
Africa: Benin (n = 1), Burkina Faso (n = 2), Côte d’Ivoire
(n = 6), Guinee Conakry (n = 1), Mali (n = 2), Nigeria (n = 2),
Senegal (n = 1) and Togo (n = 1). Demographic, clinical, bio-
logical and therapeutic information was routinely and prospec-
tively collected at these HIV care centres using a
standardized data format and submitted to the IeDEA West
Africa data coordinating centre based in Côte d’Ivoire.
Data were collected between January 1, 2002 and Decem-
ber 31, 2016 in all clinics and extended to December 31,
2018 at seven clinics in five countries (Benin, Burkina Faso,
Côte d’Ivoire (n = 3), Senegal, Togo).
Eligible patients for this study were HIV-positive adults
aged 16 years or older at ART initiation and having started
triple combination-based ART between January 1, 2002 and
December 31, 2014. Patients with missing information on
either sex, date of birth or date of ART initiation were
excluded from the analyses. We considered as CD4 count at
baseline the measure is taken at the closest date to ART initi-
ation within a window period of six months prior to and one
month after ART initiation. CD4 cell count measurement was
recommended every six months in all settings but the actual
observed frequency varied across HIV-care centres.
2.2 | Statistical analysis
Baseline characteristics of the study population were
described by median and frequency and compared by sex
using Wilcoxon rank test for quantitative variables and Fish-
er’s exact test for qualitative variables. The overall probability
of attrition at 120 months after ART initiation was described
by cumulative incidence functions of different types of drop-
outs (not returning into care after the first visit, death, loss to
follow-up (LTFU) and transfer) and compared by sex.
We distinguished two types of attrition to investigate
whether it was influenced by sex. First, we defined patients
who never returned into care after ART initiation as “No
follow-up.” Second, patients who died or were lost to follow-
up, that is not returning to the HIV-care centre for six months
or more after being engaged into care, were defined as “Loss
to care.” We used logistic regression models to assess the
association between sex and the risk of no follow-up. We then
used cause-specific hazard models to assess the association
between sex and loss to care. In this later analysis, patients
were right-censored at either the date of death, the date of
transfer, the last date for which they were known to be alive
when patients were not seen at the clinic for at least six
months without transfer or death report, the date of database
end-point, or 120 months since ART initiation, whichever
occurred first. Patients who died but had more than six
months of absence from care prior to death were considered
as lost to follow-up and were right-censored at the last date
for which they were known to be alive. Transfer of patient to
another clinic was treated as a competing risk. The overall
follow-up time was divided into three periods [Year 1 (M0-
M12), Years 2 to 4 (M13-M24) and Years 5 to 10 (M25-
M120) following ART initiation], taking into account propor-
tional hazard assumptions. The sample size for each of these
three time periods was different since it depended on the
number of patients remaining in care at the beginning of the
respective period.
In the 10-year following ART initiation, we also investigated
the association between sex and immunological response,
defined by the evolution of CD4 count. For this purpose, we
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included all participants with at least one CD4 count measure-
ment during the follow-up. We estimated CD4 change with a
mixed linear model (MLM) with random intercept and random
effect on a two-phase slope (e.g. fixed effect on CD4 change).
Slope phases were first modelled using MLM without predic-
tor, and slope change timing was then determined by compar-
ing models with different timing of the change. We retained
the best model according to the Akaike Information Criterion.
End-point definitions were the same as in the previous sur-
vival analysis. Sex and other covariates alongside their interac-
tion with time were modelled. Gain in CD4 count over time
after ART initiation was compared by sex, and the differences
were tested using Wald tests. The estimated absolute CD4 T-
cell/µL change over time was then plotted by sex. Residual
homoscedasticity and normality were checked graphically.
Sex was the main explanatory variable for both models on
attrition and immunological response. Other covariates in
these models were age at baseline (<30, 30 to 40 or
>40 years), ART starting period (2002 to 2006, 2007 to 2010
or 2011 to 2014). The logistic regression model was adjusted
on CD4 count at baseline and the cause-specific hazard mod-
els were adjusted on CD4 count as a time depending variable.
To take into account unobserved heterogeneity between clini-
cal centres, we adjusted all models for a clinic effect by includ-
ing the study site as a random effect. Clinical stage and body
mass index were described at baseline but not included in the
models due to the high frequency of missing values.
All statistical analyses were performed using SAS software
(version 9.4 for Windows, Copyright (c) 2002 to 2010 by SAS
Institute Inc., Cary, NC, USA.)
2.3 | Ethical approval
The IeDEA West Africa Collaboration obtained authorization
from the Ethics committee “Comite de Protection des Person-
nes Sud-Ouest et Outre-mer III” in Bordeaux, France to col-
lect, merge and analyse deidentified data from involved HIV
clinics in West Africa. Moreover, each West African site par-
ticipating in the study obtained authorization from its National
Ethics committee.
3 | RESULTS
3.1 | Study population characteristics
A total of 73,243 patients were registered in the IeDEA West
Africa database. Of these, 1960 were not included due to
missing information on sex (n = 4) or baseline therapeutic reg-
imen documented as monotherapy or bi-therapy (n = 1956).
The records of 71,283 patients who initiated triple-based ART
between 2002 and 2014 at one of the IeDEA West Africa
HIV care centres were included in the analyses.
Table 1 shows baseline characteristics of the study sample
according to sex. Two-thirds of patients were women (46,893/
71,283). Men were significantly older than women at ART ini-
tiation with median ages of 40.8 years (Inter Quartile Range
[IQR]: 35.1 to 47.2) and 34.0 years (IQR: 29.0 to 40.6)
respectively. Overall, CD4 count at baseline was low, but sta-
tistically significantly higher in women (184 cells/µL (IQR: 86
to 301)) than in men (140 cells/µL (IQR: 55 to 250)). A sub-
stantial proportion of patients had missing CD4 count at
baseline (29.8% in men and 28.2 in women). More than half
of both male and female patients were started on ART
between 2006 and 2010 (55.9% and 56.2% in men and
women respectively).
3.2 | Ten-year risk of attrition since ART initiation
by sex
Figure 1 represents the cumulative incidence of attrition by
sex. Men consistently had a higher probability of attrition
compared to women. The probabilities of attrition were 24%
and 19% at 12 months, 49% and 43% at 60 months and 74%
and 67% at 120 months, for men and women respectively.
Figure 2 shows the stacked plot of cumulative incidence of
attrition by attrition type (No follow-up, loss to follow-up,
death, transfer). Overall attrition was 21%, 45% and 71% at
12, 60 and 120 months following ART initiation respectively.
Overall, patients lost to follow-up accounted for 85% of
patient’s loss to care. We presented the same figure by sex in
Figure S1.
Table 2 shows predictors of no follow-up visit and attrition
during Year 1, Years 2 to 4 and Years 5 to 10 following ART
initiation. Men were at a higher risk of never returning into
care after ART initiation (5.1% in men vs. 4.0% in women,
adjusted Odds Ratios [ORa]: 1.25 [95% CI: 1.15 to 1.35]).
Throughout the 10-year period following ART initiation, men
had an increased risk of attrition compared to women: the
adjusted Hazard Ratios (HRa) were 1.22 during Year 1 (95%
CI: 1.17 to 1.27; 22.6/100 PY in men and 17.5/100 PY in
women), 1.08 during Years 2 to 4 (95% CI: 1.04 to 1.12;
10.3/100 PY in men and 8.9/100 PY in women) and 1.05 dur-
ing Years 5 to 10 (95% CI: 1.01 to 1.08; 11.9/100 PY in men
and 10.3/100 PY in women). Having less than 30 years at
ART initiation was associated with a higher risk of no-follow-
up as well as a higher risk of attrition during the follow-up.
Patients who started on ART between 2006 and 2010 or
between 2011 and 2014 were significantly more likely to be
at-risk of attrition when compared to those who started on
treatment before 2006. This was true for each of the three
calendar periods following ART initiation. Low baseline CD4
count (<100 Cells/µL) was associated with no follow-up and
time-depending CD4 count values were associated with attri-
tion over calendar time, with the risk of attrition decreasing
when CD4 increased.
3.3 | Ten-year immunological response by sex
At ART initiation, the median CD4 count was as low as 184
(86 to 301) and 140 (55 to 250) cells/µL among women and
men respectively. The median number of available CD4 mea-
surements all over the 10-year period was 5 per patient (IQR:
3 to 11). Figure 3 shows the average gain in the number of
CD4 cells during the 10 years following ART initiation by sex.
A steady increase in the first four months following ART initia-
tion was observed; with an average monthly CD4 gain of 28.3
and 30.2 cells/lL in men and women (p < 0.001) respectively.
Thereafter, this average monthly CD4 gain was much lower:
1.9 and 2.6 cells/lL in men and women (p < 0.001) respec-
tively.
Consequently, the evolution in the average number of CD4
cells was more pronounced in women than in men (Figure 3).
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The average CD4 count in women reached the 500 CD4
cells/lL threshold in their sisth year of follow-up while that in
men barely reached this threshold at the end of the 10-year
follow-up period. Of the patients who were retained in care
after 10 years since ART initiation, 65% and 44% reached the
threshold of 500 CD4 cells/lL in women and men respec-
tively.
We run three separate sensitivity analyses. The first
included baseline CD4 count as a confounder in the model
and showed similar estimates with persisting sex difference
(data not shown). The second looked at patients who remained
in care at 10 years and showed similar estimates with persist-
ing sex difference (Figure S2). The third looked at patients
with the same baseline CD4 range and showed persisting sex
differences for all CD4 ranges (<100; 100 to 200; 200 to
350; >350) (Figure S3).
4 | DISCUSSION
To the best of our knowledge, this is the first study to provide
long-term follow-up data aimed at addressing both attrition
and immunological response by sex among HIV-positive adults
on ART in West Africa. This analysis was performed on a very
large sample of 71.283 adult patients, covering 16 HIV-care
centres across eight countries over a 10-year period.
Our study confirms the findings of previous studies that
men had a higher risk of attrition when compared to women
and suggests that this increased risk in men is likely to persist
in the long-term [15,30,31]. A study from the IeDEA Southern
Africa collaboration showed an excess risk of mortality and
LTFU in men during the first 36 months following ART initia-
tion when compared to women [30]. Likewise, studies in Zim-
babwe and the Democratic Republic of Congo [8,18] found a
Table 1. Characteristics of HIV-positive adults initiating antiretroviral treatment in HIV clinics participating to the IeDEA West
Africa collaboration 2002 to 2018 (N = 71,283)
Men (N = 24,390) Women (N = 46,893)
p-valuen % n %
Median age at baseline (year) (IQR) 40.8 (35.1 to 47.2) 34.1 (28.9 to 40.7) <0.001a
Age at Baseline (years)
16 to 30 2194 9.0 14140 30.2 <0.001b
30 to 40 9107 37.3 19930 42.5
>40 13089 53.7 12823 27.3
Median CD4 cell count (Cells/µL) (IQR) 140 (55 to 250) 184 (86 to 301) <0.001a
Baseline CD4 cell count (Cells/µL)
<100 6566 38.3 9449 28.1 <0.001b
100 to 199 4536 26.5 8547 25.4
200 to 349 3988 23.3 9454 28.1
350 to 499 1215 7.1 3295 9.8
≥500 817 4.8 2913 8.7
Unknown (%) 7268 (29.8) 13235 (28.2)
Year of ART initiation
Prior to 2006 6064 24.9 10873 23.2 0.0143b
2006 to 2010 13630 55.9 26340 56.2
2011 to 2014 4696 19.3 9680 20.6
Initial ART regimen
2 NRTIs +1 PI 2625 10.8 4477 9.5 <0.001b
2 NRTIs + EFV 11219 46.0 15477 33.0
2 NRTIs + NVP 9914 40.6 25898 55.2
Other 632 2.6 1041 2.2
Body mass index
Low weight 2362 27.5 5628 31.5 <0.001b
Normal 5053 58.7 9272 51.9
Overweight 1189 13.8 2981 16.7
Unknown (%) 15786 (64.7) 29012 (61.9)
Baseline clinical stage
CDC A/B. WHO I/II 2669 49.6 6302 55.9 <0.001b
CDC C. WHO III/ IV 2711 50.4 4970 44.1
Unknown (%) 19010 (77.9) 35621 (76.0)
ap-value from Wilcoxon rank sum test.
bp-value from Fisher’s exact test.
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higher risk of attrition in men in the first 12 and 36 months
following ART initiation when compared with women. In 2014,
a study from three East African countries (Tanzania, Uganda
and Zambia) reported an increased risk of attrition among
men, however, such sex difference was not found when the
health facility benefited from a community-based approach
[14]. In a systematic review published in 2018 including 30
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Figure 1. Ten-year cumulative incidence function of attrition and 95% CI by sex. IeDEA West Africa Collaboration, 2002 to 2018.
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was associated with retention in HIV care: men had an
increased risk of attrition in resource-constrained settings
while this risk was higher in women in more developed coun-
tries [11]. These results highlight the potential role of sex on
care-seeking behaviours, which are different from one place to
one another and depend on socio-cultural and environmental
factors. This is the primary reason why differentiated care
strategies might offer certain benefits to men’s degree of
engagement in care [32].
Our results have also shown that the immunological
response was better in women compared to men in the
10 years following ART initiation, regardless of their baseline
CD4 count. Women reached the 500 CD4 threshold in their
sisth year on ART, whereas men did not reach this threshold
after the completion of the 10-year follow-up. Our findings
are in line with the results of previous studies that showed a
better immunological response in women compared to men
[33]. In sub-Saharan Africa, only a few studies investigated the
association between sex and CD4 count evolution over time.
Available data generally suggest better immunological
response in women than men, although the magnitude of the
CD4 gain varied across studies [25,30]. A study from the
IeDEA Southern Africa collaboration found a better immuno-
logical response in women than men [30] and another large-
scale study incorporating 27 cohorts throughout Africa found
no difference between men and women [34]. Such hetero-
geneity suggests that sex-specific assumptions should be taken
into account in a more specific way, specifically the beha-
vioural differences between women and men in relation to
access and use of HIV care services.
Men’s increased risk of attrition and poorer immunological
response might be partly explained by the fact that men usu-
ally initiate ART at a more advanced stage compared to
women [30,35]. Timely ART initiation in women is related to
pregnancy, allowing them to start treatment through the pre-
vention of mother-to-child transmission of HIV programmes.
On the other hand, men usually initiate ART through standard
counselling and testing services [36,37]. Studies also hypothe-
sized that perceptions of masculinity could play a role in dis-
couraging men to stay in care. Cultural belief that men are
independent and invulnerable, even in the event of a disease,
may constitute barriers to their engagement into care and
ultimately motivate an early exit from HIV care [38-43].
The extremely high cumulative attrition incidence is worth
mentioning, reaching 71% at 10 years after ART initiation,
with LTFU contributing to the largest number of attrition
cases. This was also observed in Malawi with a retention rate
as low as 48% after eight years of follow-up [7]. These LTFU
patients might be either dead or too severely ill to attend
health facilities, but they could as well be silent transfers. This
raises the issue of traceability of patients in HIV care. A
recent meta-analysis carried out in East, Southern and Central
Africa, estimated that 15% of patients classified as LTFU were
actually self-transfers [44]. Another systematic review showed
that silent transfers could account for up to 24% of LTFU
cases when tracing efforts were successfully put in place [45].
In this systematic review, the authors also reported that the
proportion of silent transfers increased over time. The transfer
might have occurred due to heavy patient load or insufficient
workforce at the health facility to efficiently track patients.
Figure 2. Ten-year stacked plot of cumulative incidence function of attrition by attrition types. IeDEA West Africa Collaboration, 2002 to
2018.
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Our attrition rate of 71% might has been overestimated since
no strategy was in place to trace LTFU patients and to check
whether they had been transferred to another HIV care facil-
ity or not. Moreover, a number of unreported deaths might
have been classified as LTFU. A recent meta-analysis under-
taken in Africa found that 21.8% of patients were confirmed
to be dead four years after the last clinical visit [44]. Mortality
among LTFU patients was known to be high in the first
months and tended to decrease over time whereas undocu-
mented transfers and treatment interruptions tended to
increase [45]. We can thus reasonably assume that the mor-
tality rate in our study was probably underestimated, however,
the magnitude of such underestimation is difficult to quantify
given the context of West Africa where there is no effective
vital registry to ascertain death.
Our study has the following limitations. HIV care facilities
selected to participate in the IeDEA West Africa collaboration
were mostly located in densely populated urban areas and
were therefore not representative of all facilities in this
region. Limitations also include issues surrounding the com-
pleteness, harmonization and management of collected data.
These limitations are inherent to this type of cohort analysis,
bringing together independent sites with site-specific modes
of operation. The lack of variables characterizing HIV care
facilities included in the study that would have allowed us to
better adjust our regression models was partly taken into
account by the integration of a random component on the
site. A large number of missing values in baseline CD4 count
was a major challenge, which was overcome to a certain
extent by sensitivity analyses focusing on the group of
patients with baseline CD4 count. Treatment interruptions
were not taken into account in this study, although they are
important to understand in order to achieve successful man-
agement of programmatic care. Immunological response
measured in our study through the estimation of CD4 gain
was important for evaluating biological response but incom-
plete. It is now necessary to apply more direct biological moni-
toring of ART success by routinely measuring the HIV-RNA
viral load so that the proportion of patients on ART achieving
an undetectable HIV-RNA viral load can be adequately
assessed. This requires the strengthening of local laboratory
capacities in the West African context largely underserved by
international and national HIV programmes.
5 | CONCLUSIONS
Our study highlights men’s vulnerability to attrition and
poorer immunological response to ART in the 10 years follow-
ing ART initiation. Understanding the reasons behind such a
persistent sex difference is important to inform HIV policies
and programmes at local level in West Africa in order to
achieve the UNAIDS 95-95-95 targets by 2030. Bearing in
mind the extremely high cumulative attrition incidence among
both women and men in the first 10-year following ART initia-
tion, innovative tracing strategies for LTFU patients are
needed for both sexes to better interpret such high attrition
rates and to support patients so that they can stay in care in
a more sustainable way.
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Figure 3. Linear mixed model on the predictive evolution in the average number of CD4 count (95% CI) among women and men in the
10 years following ART initiation. IeDEA West Africa Collaboration, 2002 to 2018.
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